Twist Bioscience Co. (NASDAQ:TWST) SVP Sells $13,941.18 in Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 297 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $46.94, for a total transaction of $13,941.18. Following the completion of the transaction, the senior vice president now owns 87,895 shares of the company’s stock, valued at approximately $4,125,791.30. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Paula Green also recently made the following trade(s):

• On Monday, August 5th, Paula Green sold 1,137 shares of Twist Bioscience stock. The shares were sold at an average price of $39.93, for a total transaction of $45,400.41.
• On Tuesday, July 2nd, Paula Green sold 322 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total transaction of $15,456.00.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST traded up $1.17 during mid-day trading on Tuesday, hitting $46.46. The company had a trading volume of 407,885 shares, compared to its average volume of 1,002,683. The firm has a fifty day moving average price of $47.05 and a 200 day moving average price of $43.14. The company has a market capitalization of $2.71 billion, a PE ratio of -13.48 and a beta of 1.76. Twist Bioscience Co. has a one year low of $14.42 and a one year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The business had revenue of $81.50 million for the quarter, compared to the consensus estimate of $77.40 million. During the same quarter last year, the firm posted ($1.01) EPS. The business’s revenue for the quarter was up 27.7% compared to the same quarter last year. Research analysts expect that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently bought and sold shares of the stock. Capital Impact Advisors LLC boosted its holdings in Twist Bioscience by 16.1% during the 2nd quarter. Capital Impact Advisors LLC now owns 20,380 shares of the company’s stock worth $1,004,000 after acquiring an additional 2,821 shares during the last quarter. Algert Global LLC boosted its holdings in Twist Bioscience by 114.8% during the second quarter. Algert Global LLC now owns 27,300 shares of the company’s stock worth $1,345,000 after purchasing an additional 14,590 shares during the last quarter. Driehaus Capital Management LLC grew its position in Twist Bioscience by 63.0% in the 2nd quarter. Driehaus Capital Management LLC now owns 388,643 shares of the company’s stock worth $19,152,000 after purchasing an additional 150,260 shares in the last quarter. Scientech Research LLC increased its stake in Twist Bioscience by 102.7% in the 2nd quarter. Scientech Research LLC now owns 31,435 shares of the company’s stock valued at $1,549,000 after buying an additional 15,924 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Twist Bioscience by 3.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,064 shares of the company’s stock worth $1,531,000 after buying an additional 1,104 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on TWST. Barclays dropped their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Guggenheim started coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They set a “buy” rating and a $53.00 price target for the company. The Goldman Sachs Group raised their price target on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, July 9th. TD Cowen raised their price target on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. Finally, Robert W. Baird raised their price target on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Twist Bioscience currently has an average rating of “Moderate Buy” and an average price target of $48.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.